Lisata Therapeutics
LSTA
24 hedge funds and large institutions have $1.59M invested in Lisata Therapeutics in 2017 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 3 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
4% more funds holding
Funds holding: 23 → 24 (+1)
0.05% less ownership
Funds ownership: 0.43% → 0.38% (-0.05%)
13% less capital invested
Capital invested by funds: $1.83M → $1.59M (-$240K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$145K |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$76.4K |
| 3 |
Creative Planning
Overland Park,
Kansas
|
+$33.8K |
| 4 |
BlackRock
New York
|
+$11.8K |
| 5 |
RFC
Regions Financial Corp
Birmingham,
Alabama
|
+$7.38K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Knoll Capital Management
Miami,
Florida
|
-$422K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$148K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$6.98K |
| 4 |
Renaissance Technologies
New York
|
-$6.68K |
LSTA Hedge Fund Activity: Q4 2017 in Review
24 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q4 2017, worth a combined $1.59M — down 13% from $1.83M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new LSTA positions and 3 closed out — a net gain of 1 holder — while 7 added to existing stakes and 3 trimmed.
The largest buyer was Panagora Asset Management, adding an estimated $145K. The largest seller was Knoll Capital Management, exiting entirely with an estimated $422K sold.
- 24 institutional investors held Lisata Therapeutics (LSTA) as of Q4 2017, up from 23 in Q3 2017.
- Funds reported $1.59M of Lisata Therapeutics stock for Q4 2017, down 13% quarter-over-quarter.
- 4 funds opened new Lisata Therapeutics positions in Q4 2017 and 3 closed out, a net change of +1 holder.
- The largest Lisata Therapeutics buyer in Q4 2017 was Panagora Asset Management, an estimated $145K added.
- The largest Lisata Therapeutics seller in Q4 2017 was Knoll Capital Management, an estimated $422K sold.
Based on aggregated 13F filings for Q4 2017.